May 12, 2021

The Fastest Growing Healthcare Stock | Skylight Health Group (SHG)

Midas Letter
Midas Letter
The Fastest Growing Healthcare Stock | Skylight Health Group (SHG)

This fast-growing healthcare stock is changing the healthcare industry. The company is simultaneously improving the economics of physician practices while improving the quality of its patients’ care. Skylight Health Group Inc (CVE: SHG, OTCMKTS: SHGFF) is a US-focused health network with medical clinics providing primary care, sub-specialty, laboratory and diagnostic testing. The company has a proprietary electronic health record system offering telemedicine service with a current patient roster of over 120,000 across 14 states.

Skylight’s business model focuses on aggressive growth where they acquire small to independent size physician practices. Once the physician practices are brought onto the Skylight platform, Skylight can help drive efficiencies and instill the technology/capabilities to help transform the practice to the new US reimbursement model.

This new capitation reimbursement insurance model could help ensure care delivery is based on quality, not quantity. This means patients will have more time with the medical professional while allowing for a much higher margin revenue business for the primary care industry. This shift could transform patient care and revenue growth up to 500% or more.

“Our model isn’t how do you flip a EBIDTA in the next 2-3 years, it’s how do you build the biggest business base possible today on a fee-for-service model. When that converts into capitation, you’re going to see a tremendous increase in overall economics and patient care.” – Skylight Health CEO Prad Sekar

Watch the full interview to learn about Skylight’s acquisition strategy and how they fly under the radar of its much larger competitors to acquire small physician practices.


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.